Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations

nork Pfeffer, Gerald, Burke, Ailbhe, Yu-Wai-Man, Patrick, Compston, D. Alastair S., Chinnery, Patrick F.
Argitaratua 2013

Immune competence after alemtuzumab treatment of multiple sclerosis

nork McCarthy, Claire L., Tuohy, Orla, Compston, D. Alastair S., Kumararatne, Dinakantha S., Coles, Alasdair J., Jones, Joanne L.
Argitaratua 2013

Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?

nork Cerqueira, João J, Compston, D Alastair S, Geraldes, Ruth, Rosa, Mario M, Schmierer, Klaus, Thompson, Alan, Tinelli, Michela, Palace, Jacqueline
Argitaratua izan da J Neurol Neurosurg Psychiatry (2018)

Mesenchymal Stem Cells Lack Efficacy in the Treatment of Experimental Autoimmune Neuritis despite In Vitro Inhibition of T-Cell Proliferation

nork Sajic, Marija, Hunt, David P. J., Lee, Woojin, Compston, D. Alastair S., Schweimer, Judith V., Gregson, Norman A., Chandran, Siddharthan, Smith, Kenneth J.
Argitaratua 2012

Genetic variation in nitric oxide synthase 2A (NOS2A) and risk for multiple sclerosis

nork Barcellos, Lisa F., Ramsay, Patricia P., Caillier, Stacy J., Sawcer, Stephen, Haines, Jonathan, Schmidt, Silke, Pericak-Vance, Margaret, Compston, D. Alastair S., Gabatto, Pablo, Hauser, Stephen L., Oksenberg, Jorge R.
Argitaratua 2008

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

nork Giovannoni, Gavin, Cohen, Jeffrey A., Coles, Alasdair J., Hartung, Hans-Peter, Havrdova, Eva, Selmaj, Krzysztof W., Margolin, David H., Lake, Stephen L., Kaup, Susan M., Panzara, Michael A., Compston, D. Alastair S.
Argitaratua izan da Neurology (2016)

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study

nork Wray, Sibyl, Havrdova, Eva, Snydman, David R, Arnold, Douglas L, Cohen, Jeffrey A, Coles, Alasdair J, Hartung, Hans-Peter, Selmaj, Krzysztof W, Weiner, Howard L, Daizadeh, Nadia, Margolin, David H, Chirieac, Madalina C, Compston, D Alastair S
Argitaratua izan da Mult Scler (2018)

Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223

nork Steingo, Brian, Al Malik, Yaser, Bass, Ann D., Berkovich, Regina, Carraro, Matthew, Fernández, Óscar, Ionete, Carolina, Massacesi, Luca, Meuth, Sven G., Mitsikostas, Dimos D., Pardo, Gabriel, Simm, Renata Faria, Traboulsee, Anthony, Choudhry, Zia, Daizadeh, Nadia, Compston, D. Alastair S.
Argitaratua izan da J Neurol (2020)

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

nork Coles, Alasdair J., Arnold, Douglas L., Bass, Ann D., Boster, Aaron L., Compston, D. Alastair S., Fernández, Óscar, Havrdová, Eva Kubala, Nakamura, Kunio, Traboulsee, Anthony, Ziemssen, Tjalf, Jacobs, Alan, Margolin, David H., Huang, Xiaobi, Daizadeh, Nadia, Chirieac, Madalina C., Selmaj, Krzysztof W.
Argitaratua izan da Ther Adv Neurol Disord (2021)

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS

nork Arnold, Douglas L., Fisher, Elizabeth, Brinar, Vesna V., Cohen, Jeffrey A., Coles, Alasdair J., Giovannoni, Gavin, Hartung, Hans-Peter, Havrdova, Eva, Selmaj, Krzysztof W., Stojanovic, Miroslav, Weiner, Howard L., Lake, Stephen L., Margolin, David H., Thomas, David R., Panzara, Michael A., Compston, D. Alastair S.
Argitaratua izan da Neurology (2016)

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

nork Coles, Alasdair J., Cohen, Jeffrey A., Fox, Edward J., Giovannoni, Gavin, Hartung, Hans-Peter, Havrdova, Eva, Schippling, Sven, Selmaj, Krzysztof W., Traboulsee, Anthony, Compston, D. Alastair S., Margolin, David H., Thangavelu, Karthinathan, Chirieac, Madalina C., Jody, Darlene, Xenopoulos, Panos, Hogan, Richard J., Panzara, Michael A., Arnold, Douglas L.
Argitaratua izan da Neurology (2017)

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

nork Havrdova, Eva, Arnold, Douglas L., Cohen, Jeffrey A., Hartung, Hans-Peter, Fox, Edward J., Giovannoni, Gavin, Schippling, Sven, Selmaj, Krzysztof W., Traboulsee, Anthony, Compston, D. Alastair S., Margolin, David H., Thangavelu, Karthinathan, Rodriguez, Claudio E., Jody, Darlene, Hogan, Richard J., Xenopoulos, Panos, Panzara, Michael A., Coles, Alasdair J.
Argitaratua izan da Neurology (2017)